Don’t Miss The Train: Pharma's Future Holds Deeper Digital Deals, Outcome-Based Pacts
Executive Summary
Asked by Scrip to name two big changes coming pharma's way, Merck KGAA Healthcare CEO Belén Garijo identified artificial intelligence and outcome-based pacts as 'ways of the future'.
You may also be interested in...
Deal Watch: Ionis Out-Licenses Pair Of Generation 2.5 Antisense Candidates
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
Merck KGaA Highlights Mavenclad Advances In Tough Quarter
Merck KGaA's brace of new products started to garner sales in the third quarter, but the big pharma maintained its 2017 guidance at the lower end of the forecast range in the face of increasing competition to its established pharmaceutical products and to its liquid crystal materials, and currency headwinds.
CEO Schwan Says Roche's Founding Families Let Him Operate Long Term
Roche's CEO Severin Schwan says corporate nurturing and support consistently given by the pharma's founding families have helped him take the long view, even in difficult times.